Active	Status	Sponsor type	Region	Phase	Filter
3 Active 2 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
OMNIvance (xeruborbactam) / Shionogi
NCT06547554: A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants	Recruiting	1	40	US	Xeruborbactam, QPX7728, Cefiderocol, Xeruborbactam/Cefiderocol, Dextrose 5% in water	Qpex Biopharma, Inc., Shionogi Inc., Biomedical Advanced Research and Development Authority	Bacterial Infections	12/25	12/25
NCT06079775: P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants	Recruiting	1	72	RoW	Xeruborbactam Oral Prodrug, QPX7831, Ceftibuten, Xeruborbactam Oral Prodrug Placebo, QPX7831 Placebo, Ceftibuten Placebo	Qpex Biopharma, Inc., Shionogi Inc., Biomedical Advanced Research and Development Authority	Bacterial Infections	09/24	12/24
NCT06157242: PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment	Not yet recruiting	1	32	NA	Xeruborbactam Oral Prodrug, QPX7831, Ceftibuten	Qpex Biopharma, Inc., Shionogi Inc., Biomedical Advanced Research and Development Authority	Bacterial Infections	02/25	06/25